Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type i receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure

Circulation: Heart Failure

Volumn 4, Issue 6, 2011, Pages 770-778

  Boerrigter, Guido ^a   Lark, Michael W ^b   Whalen, Erin J ^b   Soergel, David G ^b   Violin, Jonathan D ^b   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

^b TREVENA INC   (United States)

Author keywords

Angiotensin II; Drugs; Heart failure; Pharmacology; Receptors

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA ARRESTIN; TRV 120027; UNCLASSIFIED DRUG; LIGAND; OLIGOPEPTIDE; RETINA S ANTIGEN; SARCOSINE ARGINYL VALYL TYROSYL ISOLEUCYL HISTIDYL PROLYL ALANINE; SARCOSINE-ARGINYL-VALYL-TYROSYL-ISOLEUCYL-HISTIDYL-PROLYL-ALANINE; SODIUM;

ANESTHESIA; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG DOSE ESCALATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART OUTPUT; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SODIUM URINE LEVEL; SYSTEMIC VASCULAR RESISTANCE; ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; HEART; KIDNEY; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; URINE; VASCULAR RESISTANCE;

ANIMALS; ARRESTINS; BLOOD PRESSURE; CARDIAC OUTPUT; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HEART; HEART FAILURE; KIDNEY; LIGANDS; MALE; OLIGOPEPTIDES; RECEPTOR, ANGIOTENSIN, TYPE 1; SODIUM; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84856343982     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.962571     Document Type: Article

References (33)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics: 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov. 2010;9:373-386.
3. Benovic JL, Kuhn H, Weyand I, Codina J, Caron MG, Lefkowitz RJ. Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). Proc Natl Acad Sci U S A. 1987;84: 8879-8882.
4. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science. 1990; 248:1547-1550.
5. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999;283:655-661.
6. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci U S A. 2001;98: 2449-2454. (Pubitemid 32209502)
7. Sun Y, Cheng Z, Ma L, Pei G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem. 2002;277:49212-49219. (Pubitemid 36014350)
8. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science. 2000;290:1574-1577.
9. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, Roden DM, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest. 2005;115:3045-3056. (Pubitemid 41567570)
10. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seventransmembrane receptors. Trends Pharmacol Sci. 2007;28:416-422.
11. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of betaarrestin- and G protein-biased agonists. Trends Mol Med. 2011;17: 126-139.
12. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, Coffman TM, Rockman HA, Lefkowitz RJ. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A. 2006;103:16284-16289. (Pubitemid 44715188)
13. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther. 2010;335:572-579.
14. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119: e391-e479.
15. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-2442.
16. Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999;100:2443-2448.
17. Lisy O, Lainchbury JG, Leskinen H, Burnett JC Jr. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001;37:1089-1094. (Pubitemid 32304009)
18. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R897-R901. (Pubitemid 46207745)
19. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007;49:1128-1133. (Pubitemid 351664312)
20. Fuhr J, Kaczmarczyk K, Kruttgen C. Eine einfache colorimetrische Methode zur Inulinbestimmung fuer Nieren-Clearance-Untersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr. 1955;33: 729-733.
21. Jiang NS, Machacek D, Wadel OP. Further study on the two-column plasma catecholamine assay. Mayo Clin Proc. 1976;51:112-116.
22. Chan DP, Sandok EK, Aarhus LL, Heublein DM, Burnett JC Jr. Renalspecific actions of angiotensin II receptor antagonism in the anesthetized dog. Am J Hypertens. 1992;5:354-360.
23. Clark JK, Barker HG. Studies of renal oxygen consumption in man, I: the effect of tubular loading (PAH), water diuresis and osmotic (mannitol) diuresis. J Clin Invest. 1951;30:745-750.
24. Cargill WH, Hickam JB. The oxygen consumption of the human kidney. J Clin Invest. 1948;27:528.
25. Lassen NA, Munck O, Thaysen JH. Oxygen consumption and sodium reabsorption in the kidney. Acta Physiol Scand. 1961;51:371-384.
26. Kiil F, Aukland K, Refsum HE. Renal sodium transport and oxygen consumption. Am J Physiol. 1961;201:511-516.
27. Kurnik BR, Weisberg LS, Kurnik PB. Renal and systemic oxygen consumption in patients with normal and abnormal renal function. J Am Soc Nephrol. 1992;2:1617-1626.
28. Redfors B, Bragadottir G, Sellgren J, Sward K, Ricksten SE. Acute renal failure is NOT an "acute renal success": a clinical study on the renal oxygen supply/demand relationship in acute kidney injury. Crit Care Med. 2010;38:1695-1701.
29. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci U S A. 2009;106:5825-5830.
30. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation. 2006;113:2221-2228.
31. Hussain MB, MacAllister RJ, Hobbs AJ. Reciprocal regulation of cGMPmediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol. 2001;280:H1151-H1159.
32. Madhani M, Okorie M, Hobbs AJ, MacAllister RJ. Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo. Br J Pharmacol. 2006;149:797-801. (Pubitemid 44748072)
33. Matsukawa K, Ninomiya I, Nishiura N. Effects of anesthesia on cardiac and renal sympathetic nerve activities and plasma catecholamines. Am J Physiol. 1993;265:R792-R797.